These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 31550190

  • 1. Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.
    Edelman SV, Ermakova A, Xiong Y, Sieradzan R, Taylor SD.
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1420-1431. PubMed ID: 31550190
    [Abstract] [Full Text] [Related]

  • 2. Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus.
    Raval AD, Nguyen MH, Zhou S, Grabner M, Barron J, Quimbo R.
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1111-1123. PubMed ID: 31556817
    [Abstract] [Full Text] [Related]

  • 3. Clinical and Economic Outcomes of Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-bolus Insulin (MDI) Therapy: A Retrospective Cohort Study.
    Brixner D, Ermakova A, Xiong Y, Sieradzan R, Sacks N, Cyr P, Taylor SD.
    Clin Ther; 2019 Feb; 41(2):303-313.e1. PubMed ID: 30709610
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M, Peng X, Geremakis C, Bae J.
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control.
    Karkare S, Fridman M, Dang-Tan T, Lu J, Smolarz BG, DeKoven M, Iyer NN.
    J Manag Care Spec Pharm; 2019 Jun; 25(6):658-668. PubMed ID: 30730232
    [Abstract] [Full Text] [Related]

  • 10. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
    Levin PA, Zhou S, Gill J, Wei W.
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
    [Abstract] [Full Text] [Related]

  • 11. Factors Associated with Diabetes-Related Clinical Inertia in a Managed Care Population and Its Effect on Hemoglobin A1c Goal Attainment: A Claims-Based Analysis.
    Ruiz-Negrón N, Wander C, McAdam-Marx C, Pesa J, Bailey RA, Bellows BK.
    J Manag Care Spec Pharm; 2019 Mar; 25(3):304-313. PubMed ID: 30816810
    [Abstract] [Full Text] [Related]

  • 12. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
    Mocarski M, Yeaw J, Divino V, DeKoven M, Guerrero G, Langer J, Thorsted BL.
    J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L, Zhou S, Pinsky BW, Buysman EK, Baser O.
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [Abstract] [Full Text] [Related]

  • 15. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D, Rubin DT, Mease P, Mittal M, Liu H, Davis M, Ganguli A, Fendrick AM.
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [Abstract] [Full Text] [Related]

  • 16. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US.
    Perez-Nieves M, Kabul S, Desai U, Ivanova JI, Kirson NY, Cummings AK, Birnbaum HG, Duan R, Cao D, Hadjiyianni I.
    Curr Med Res Opin; 2016 Jul; 32(4):669-80. PubMed ID: 26703951
    [Abstract] [Full Text] [Related]

  • 17. Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.
    Mody R, Huang Q, Yu M, Patel H, Zhang X, Wang L, Grabner M.
    BMJ Open Diabetes Res Care; 2019 Jul; 7(1):e000884. PubMed ID: 31875137
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of Diabetes Treatment-Related Attributes on Costs to Type 2 Diabetes Patients in a Real-World Population.
    Meng J, Casciano R, Lee YC, Stern L, Gultyaev D, Tong L, Kitio-Dschassi B.
    J Manag Care Spec Pharm; 2017 Apr; 23(4):446-452. PubMed ID: 28345434
    [Abstract] [Full Text] [Related]

  • 20. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes.
    Bibeau WS, Fu H, Taylor AD, Kwan AY.
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1338-1347. PubMed ID: 27783549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.